A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Recruiting now

Conditions studied: Psoriasis

In brief

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

Key facts

Study ID

NCT05744466

Run by

Bristol-Myers Squibb

People needed

1500

Starts

2022-09-30

Expected to finish

2027-12-10

Last updated by the study team

2024-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have been diagnosed with plaque psoriasis by a dermatologist
• Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
• Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

You may not qualify if…

• Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
• Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

Where it is running

• Local Institution — Waltham, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.